WFIPP has been invited to take part in a Panel Discussion at the 24th Pharmacovigilance 2021 (Virtual Conference) on February 24 and 25, 2021. The topic is – Patient Centric – Pharmacovigilance & Patient Safety.


After the successful journey of a series of 23 Pharmacovigilance conferences, Virtue Insight is proud to announce its 24th Pharmacovigilance 2021. We have been delivering the conference through close collaboration with the industry leaders for more than a decade. Considering the current pandemic situation, for the 2021st  edition, the agenda includes a host of new and exciting features. Take a chance and make it count by attending this conference to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level.

The global pharmacovigilance market size was estimated at USD 4.87 billion in 2019 is expected to increase at a compound annual growth rate (CAGR) of 13.2% from 2020 to 2027. An increase in the prevalence of chronic diseases has led to an increase in drug consumption worldwide. Thereby demand for new drug development via extensive clinical trials has increased.

This event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.

It gives me great pleasure in welcoming all of you to the Virtue Insight’s 24th Pharmacovigilance 2021.  I wish and pray that all our efforts will be beneficial to our industries and to our all at large.


  • Overcoming this Pandemic Issues – Drug Safety Strategy for Pharmaceutical organisations
  • Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration
  • Key factors driving the current global Pharmacovigilance (PV) market?
  • Pharmacovigilance and assessment of drug safety reports during COVID 19
  • What are the market opportunities, market risk and market overview of the (PV) market?
  • PV Audit & Inspections – Keeping on the right side of Inspectors
  • Documentation (RMPs, PSURs, PADERs, PBRERs)
  • Practical approaches – Quality, Safety  & Signal Detection
  • Medical devices – Increasing safety perspective
  • Improving patient safety
  • New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
  • Brexit Implications for the Pharmaceutical (pharmacovigilance) Industry
  • RoW – Recent developments and future perspectives
  • The developing regulatory framework in advanced and developing markets – EU, USA & ROW
  • Be part of a major networking opportunity


CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

  • Pharmacovigilance
  • Pharmacoepidemiology
  • Pharmacogenomics
  • Drug/Product Safety
  • Drug Development
  • Information and Clinical Data Management
  • Clinical Pharmacology
  • Clinical Safety
  • Periodical safety update Reports
  • Risk Management
  • Research & Development
  • Quality Assurance
  • Patient Safety
  • Signal Detection
  • Safety Surveillance
  • Outcomes Research
  • Data Analysis
  • Epidemiology
  • Medical Affairs
  • Regulatory Affairs and Compliance
  • Information technology
  • Sales and Marketing


E-Certificate of attendance would be provided to attendees on request, upon completion of conference